Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 187

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 187
---
 
 severe adverse events (SAE). Profusa anticipates the start of its next validation study in the first half of 2026 and regulatory submission    
 in early 2026. Profusa believes that its technological approach may create advantages to current glucose monitoring solutions on the market    
 to substantially increase the number of users who can benefit from this data stream from the current type 1 diabetes population to             
 the much larger type 2 and pre-diabetes populations, as well as any individuals outside of these aforementioned populations interested         
 in having access to long-lasting continuous glucose data. Across all of these four segments, Profusa anticipates a total addressable market    
 of just over 500 million patients across the United States and European Union by end of 2025.                                                  |

| ● | Potential future product revenues from other analytes such as lactate, CO2, ethanol, pH and other important         
 metrics in the management of other chronic conditions, which may be targeted by Profusa’s research and development. |

| ● | Potential future revenues from the data streams of the above applications, which could become a key enabler                                     
 to achieve the technology-enabled future for healthcare being brought to bear by nascent healthcare growth sectors such as telemedicine         
 and health and wellness coaching platforms. The total value of this space is expected to reach almost $400 billion by end of 2028.              
 While these platforms are beginning to gain users and engagement demonstrating some degree of clinical utility, Profusa believes that           
 the growth of these platforms suffer from the lack of real time clinical data. In the field of telemedicine, physician and patient interactions 
 still require visits to labs for blood test to inform physician diagnosis and feedback. In the case of coaching platforms, the lack of          
 inexpensive real time data relegates the business model to rely on expensive technologies and nurses/coaches to provide the clinical feedback   
 to users. Profusa believes that, at scale, the data Profusa’s platform generates from its initial products will be a key enabler                
 for the productivity and business models for both of these sectors to expand and reach more of their full potential. Profusa’s plan             
 is to partner and provide such data streams as a further growth driver for Profusa.                                                             |

Profusa’s Addressable Market

There have been many attempts
to develop technologies that provide real time biochemistry and biomarker data for individuals. The most compelling use case has been
for measurement of glucose in the management of diabetes. The first traditional approach to glucose measurement is to take measurements
at discrete